Somatostatinoma syndrome. Clinical, morphological and metabolic features and therapeutic aspects.
A case of somatostatinoma syndrome in a 30-year-old woman is presented. Basal levels of growth hormone and of pancreatic and gastric hormones were reduced and the response of growth hormone, insulin and C-peptide to stimuli such as arginine, glucose, glibenclamide and calcium was virtually abolished. Similarly, gastric acid secretion, pancreatic exocrine function and intestinal absorption were significantly reduced. On the other hand, basal and stimulated levels of adrenocorticotropic hormone (ACTH), luteinizing hormone (LH), follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH) were within the normal range. Plasma somatostatin-like immunoreactivity was increased to 600-2,000 pg/ml (normal: 88-140 pg/ml). Immunocytochemical studies demonstrated the presence of somatostatin immunoreactive material in the primary tumour in the head of the pancreas and in the liver metastases. In spite of two courses of chemotherapy with streptozotocin and 5-fluorouracil the patient died due to liver failure 5 months after the first admission to hospital.
D007516:Adenoma, Islet Cell / Q000503:physiopathology*; D000328:Adult; D002096:C-Peptide / Q000097:blood; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D008113:Liver Neoplasms / Q000556:secondary / Q000648:ultrastructure; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000503:physiopathology*; D010191:Pancreatic Polypeptide / Q000032:analysis; D010907:Pituitary Hormones / Q000032:analysis; D013004:Somatostatin / Q000097:blood; D013005:Somatostatinoma / Q000188:drug therapy / Q000503:physiopathology* / Q000556:secondary; D013311:Streptozocin / Q000627:therapeutic use; D014994:Xylose / Q000378:metabolism
D002096:C-Peptide; D007328:Insulin; D010907:Pituitary Hormones; D013004:Somatostatin; D010191:Pancreatic Polypeptide; D013311:Streptozocin; D014994:Xylose